GGrantIndex
← Leaderboards

Lisa M Coussens

Oregon Health & Science University

Google Scholar ↗PubMed ↗ORCID ↗
$10,998,130
Attributed
$16,546,336
Total exposure
17
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,780,029 · 19

By mechanism

R01$8,943,398 · 6
P30$3,742,646 · 3
U54$3,717,663 · 6
U01$2,948,146 · 1
T32$1,790,198 · 1
S10$403,978 · 1

Top collaborators

Most similar at Oregon Health & Science University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsCellsTumorImmuneNeoplasticMolecularResponsePathway InteractionsBaseMouse ModelTissuesLeukocytesProgramsMalignant Breast NeoplasmCancer CellInflammationGeneticSignal TransductionCharacteristicsInsightNeoplastic CellIn VivoDrug ResistanceCancer Therapy

Grant awards (71)

Integrated Training in Quantitative and Experimental Cancer Systems Biology$444,216
T32 · FY2025 · CA · contact PI
Immunometabolic dysregulations in the offspring of obese mothers$234,000
R21 · FY2025 · HD
Environmental Exposures, Reproductive Windows, and Social Drivers of Young-Onset Breast Cancer$156,000
P30 · FY2025 · CA · contact PI
Biology of the Hormonal Regulation of Cancer and Immuno Oncology Outcomes Research Proposal.$150,000
P30 · FY2025 · CA · contact PI
OHSU Knight Cancer Institute$2,891,535
P30 · FY2024 · CA · contact PI
Integrated Training in Quantitative and Experimental Cancer Systems Biology$437,869
T32 · FY2024 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$546,688
U01 · FY2023 · CA
Integrated Training in Quantitative and Experimental Cancer Systems Biology$418,222
T32 · FY2023 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$547,032
U01 · FY2022 · CA
Integrated Training in Quantitative and Experimental Cancer Systems Biology$247,408
T32 · FY2022 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$714,330
U01 · FY2021 · CA
Integrated Training in Quantitative and Experimental Cancer Systems Biology$242,483
T32 · FY2021 · CA · contact PI
Cancer Biology$1,628
P30 · FY2021 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$560,027
U01 · FY2020 · CA
Cancer Biology$33,318
P30 · FY2020 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$580,069
U01 · FY2019 · CA
Cancer Biology$48,413
P30 · FY2019 · CA · contact PI
Cancer Biology$48,413
P30 · FY2018 · CA · contact PI
Cancer Biology$16,564
P30 · FY2018 · CA · contact PI
Cancer Biology$14,999
P30 · FY2018 · CA · contact PI
Cancer Biology$8,331
P30 · FY2018 · CA · contact PI
Cancer Biology$48,413
P30 · FY2017 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$354,487
U54 · FY2015 · CA · contact PI
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$354,487
U54 · FY2015 · CA · contact PI
Regulating the Immune Microenvironment in Breast Cancer$319,550
R01 · FY2015 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$504,942
U54 · FY2014 · CA · contact PI
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$504,942
U54 · FY2014 · CA · contact PI
Regulating the Immune Microenvironment in Breast Cancer$309,964
R01 · FY2014 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$365,455
U54 · FY2013 · CA · contact PI
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$365,455
U54 · FY2013 · CA · contact PI
Regulating the Immune Microenvironment in Breast Cancer$300,377
R01 · FY2013 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$411,273
U54 · FY2012 · CA · contact PI
Vevo 2100 Ultrasound System$403,978
S10 · FY2012 · OD · contact PI
Regulating the Immune Microenvironment in Breast Cancer$319,550
R01 · FY2012 · CA · contact PI
Regulation of Inflammation-Associated Epithelial Cancer Development$309,964
R01 · FY2012 · CA · contact PI
Inflammation and Lung Carcinogenesis$284,744
R01 · FY2012 · CA
Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches$261,106
R01 · FY2012 · CA · contact PI
Regulating the Immune Microenvironment in Breast Cancer$1
R01 · FY2012 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$400,001
U54 · FY2011 · CA · contact PI
Regulating the Immune Microenvironment in Breast Cancer$320,588
R01 · FY2011 · CA · contact PI
Regulation of Inflammation-Associated Epithelial Cancer Development$310,970
R01 · FY2011 · CA · contact PI
Inflammation and Lung Carcinogenesis$284,744
R01 · FY2011 · CA
Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches$248,513
R01 · FY2011 · CA · contact PI
MOUSE PATHOLOGY$76,045
P30 · FY2011 · CA · contact PI
Regulation of Inflammation-Associated Epithelial Cancer Development$320,588
R01 · FY2010 · CA · contact PI
Inflammation and Lung Carcinogenesis$293,550
R01 · FY2010 · CA
Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches$256,199
R01 · FY2010 · CA · contact PI
MOUSE PATHOLOGY$64,368
P30 · FY2010 · CA · contact PI
Regulation of Inflammation-Associated Epithelial Cancer Development$320,588
R01 · FY2009 · CA · contact PI
Inflammation and Lung Carcinogenesis$293,550
R01 · FY2009 · CA
Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches$256,199
R01 · FY2009 · CA · contact PI
MOUSE PATHOLOGY$64,046
P30 · FY2009 · CA · contact PI
Regulation of Inflammation-Associated Epithelial Cancer Development$320,588
R01 · FY2008 · CA · contact PI
Inflammation and Lung Carcinogenesis$293,391
R01 · FY2008 · CA
CORE 2 DB5: PROTEOLYTIC PATHWAYS IN ACUTE VASCULAR RESPONSE$116,538
U54 · FY2008 · RR · contact PI
MOUSE PATHOLOGY$65,009
P30 · FY2008 · CA · contact PI
Microenvironmental Regulation of Tumor Progression$319,620
R01 · FY2007 · CA · contact PI
CORE 2 DB5: PROTEOLYTIC PATHWAYS IN ACUTE VASCULAR RESPONSE$111,684
U54 · FY2007 · RR · contact PI
MOUSE PATHOLOGY$55,564
P30 · FY2007 · CA · contact PI
Microenvironmental Regulation of Tumor Progression$329,166
R01 · FY2006 · CA · contact PI
Regulation of Epithelial Cancer by MMP-9/gelatinase B$329,166
R01 · FY2006 · CA · contact PI
CORE 2 DB5: PROTEOLYTIC PATHWAYS IN ACUTE VASCULAR RESPONSE$120,385
U54 · FY2006 · RR · contact PI
Microenvironmental Regulation of Tumor Progression$337,088
R01 · FY2005 · CA
Regulation of Epithelial Cancer by MMP-9/gelatinase B$337,088
R01 · FY2005 · CA
CORE 2 DB5: PROTEOLYTIC PATHWAYS IN ACUTE VASCULAR RESPONSE$108,014
U54 · FY2005 · RR
Microenvironmental Regulation of Tumor Progression$337,088
R01 · FY2004 · CA
Regulation of Epithelial Cancer by MMP-9/gelatinase B$337,088
R01 · FY2004 · CA
Regulation of Epithelial Cancer by MMP-9/gelatinase B$336,532
R01 · FY2003 · CA
Microenvironmental Regulation of Tumor Progression$327,921
R01 · FY2003 · CA
Regulation of Epithelial Cancer by MMP-9/gelatinase B$327,917
R01 · FY2002 · CA
Core--Mouse pathology laboratory$0
P30 · FY2002 · CA